Last reviewed · How we verify
NCT07285408: SARC-NMIBC
Sarcopenia and NMIBC Prognosis Study
trial in Bladder Cancer Cell Transitional in 150 participants. Not yet recruiting.
12 July 2027
Quick facts
| Lead sponsor | General Hospital Sveti Duh |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 2 March 2026 |
| Primary completion | 12 July 2027 |
| Estimated completion | 9 July 2029 |
Conditions studied
- Bladder Cancer Cell Transitional — all drugs for Bladder Cancer Cell Transitional →
Sponsor
General Hospital Sveti Duh
Who can join
18 and older, any sex, with Bladder Cancer Cell Transitional. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate whether body composition abnormalities (sarcopenia, myosteatosis, and obesity) and nutritional status influence the risk of recurrence and progression in adult patients with non-muscle-invasive bladder cancer (NMIBC). The main questions it aims to answer are: Do sarcopenia, myosteatosis, obesity, or malnutrition increase the likelihood of NMIBC recurrence and progression? Can clinical, laboratory, and CT-derived body composition parameters serve as predictive biomarkers that improve individualized risk stratification? Participants will undergo routine clinical and radiologic assessments, including: * completion of the SARC-F and NRS nutritional screening questionnaires * anthropometric measurements (BMI, waist circumference) * laboratory evaluation including serum albumin and testosterone * CT-based assessment of skeletal muscle index (SMI) and muscle density (SMD) * standard TURBT and structured follow-up with cystoscopy, cytology, imaging, and clinical evaluations to document recurrence and progression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07285408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other General Hospital Sveti Duh trials
Trials by the same sponsor.
- NCT07277556 — TURP Outcome Prediction Calculator Study · not yet recruiting
- NCT04837924 — Fascia Iliaca Compartment Block for Pain Management in Hip Fracture Patients · Phase 4 · completed
- NCT04607031 — Prognostic Accuracy of ST2 Dynamics in Ischemic Stroke Outcome · completed
- NCT04276519 — Position-Induced Opening of the Intervertebral Foramen is Efficient to Treat an Acute Lumbosacral Radiculopathy Caused b · NA · completed
- NCT03085862 — Lung Ultrasonography and Extravascular Lung Water · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07285408 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General Hospital Sveti Duh
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07285408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing